An evaluation of cytokine and cellular immune responses to heterologous prime-boost vaccination with influenza A/H7N7-A/H7N9 inactivated vaccine

References

• Bresson JL, Perronne C, Launay O, Gerdil C, Saville M, Wood J, Höschler K, Zambon MC. Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial. Lancet. 2006;367:1657–64. doi:https://doi.org/10.1016/S0140-6736(06)68656-X.
   PubMed Web of Science ®Google Scholar
• Jackson LA, Campbell JD, Frey SE, Edwards KM, Keitel WA, Kotloff KL, Berry AA, Graham I, Atmar RL, Creech CB, et al. Effect of varying doses of a monovalent H7N9 influenza vaccine with and without AS03 and MF59 adjuvants on immune response: a randomized clinical trial. JAMA. 2015;314(3):237–46. doi:https://doi.org/10.1001/jama.2015.7916.
   PubMed Web of Science ®Google Scholar
• Atmar RL, Keitel WA. Adjuvants for pandemic influenza vaccines. Curr Top Microbiol Immunol. 2009;333:323–44. doi:https://doi.org/10.1007/978-3-540-92165-3_16.
   PubMedGoogle Scholar
• Goji NA, Nolan C, Hill H, Wolff M, Noah DL, Williams TB, Rowe T, Treanor JJ. Immune responses of healthy subjects to a single dose of intramuscular inactivated influenza A/Vietnam/1203/2004 (H5N1) vaccine after priming with an antigenic variant. J Infect Dis. 2008;198:635–41. doi:https://doi.org/10.1086/590916.
   PubMed Web of Science ®Google Scholar
• Goodman JL. Investing in immunity: prepandemic immunization to combat future influenza pandemics. Clin Infect Dis. 2016;62:495–98. doi:https://doi.org/10.1093/cid/civ957.
   PubMed Web of Science ®Google Scholar
• El Sahly HM, Atmar RL, Patel SM, Bellamy A, Liu L, Hong W, Zhu H, Guan Y, Keitel WA, DMID 13-0033 Vaccine Study Group. Safety and immunogenicity of an 8 year interval heterologous prime-boost influenza A/H7N7-H7N9 vaccination. Vaccine. 2019;37:2561–68. doi:https://doi.org/10.1016/j.vaccine.2019.03.071.
   PubMed Web of Science ®Google Scholar
• Babu TM, Levine M, Fitzgerald T, Luke C, Sangster MY, Jin H, Topham D, Katz J, Treanor J, Subbarao K, et al. Live attenuated H7N7 influenza vaccine primes for a vigorous antibody response to inactivated H7N7 influenza vaccine. Vaccine. 2014;32(50):6798–804. doi:https://doi.org/10.1016/j.vaccine.2014.09.070.
   PubMed Web of Science ®Google Scholar
• Nayak JL, Fitzgerald TF, Richards KA, Yang H, Treanor JJ, Sant AJ. CD4+ T-cell expansion predicts neutralizing antibody responses to monovalent, inactivated 2009 pandemic influenza A(H1N1) virus subtype H1N1 vaccine. J Infect Dis. 2013;207:297–305. doi:https://doi.org/10.1093/infdis/jis684.
   PubMed Web of Science ®Google Scholar
• Bentebibel SE, Lopez S, Obermoser G, Schmitt N, Mueller C, Harrod C, et al. Induction of ICOS+CXCR3+CXCR5+ TH cells correlates with antibody responses to influenza vaccination. Sci Transl Med. 2013;5:176ra32. doi:https://doi.org/10.1126/scitranslmed.3005191.
   PubMed Web of Science ®Google Scholar
• Mohanty S, Joshi SR, Ueda I, Wilson J, Blevins TP, Siconolfi B, Meng H, Devine L, Raddassi K, Tsang S, et al. Prolonged proinflammatory cytokine production in monocytes modulated by interleukin 10 after influenza vaccination in older adults. J Infect Dis. 2015;211(7):1174–84. doi:https://doi.org/10.1093/infdis/jiu573.
   PubMed Web of Science ®Google Scholar
• Couch RB, Patel SM, Wade-Bowers CL, Nino D. A randomized clinical trial of an inactivated avian influenza A (H7N7) vaccine. PLoS One. 2012;7:e49704. doi:https://doi.org/10.1371/journal.pone.0049704.
   PubMed Web of Science ®Google Scholar
• Leroux-Roels I, Borkowski A, Vanwolleghem T, Drame M, Clement F, Hons E, et al. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet. 2007;370:580–89. doi:https://doi.org/10.1016/S0140-6736(07)61297-5.
   PubMed Web of Science ®Google Scholar
• Morel S, Didierlaurent A, Bourguignon P, Delhaye S, Baras B, Jacob V, et al. Adjuvant System AS03 containing alpha-tocopherol modulates innate immune response and leads to improved adaptive immunity. Vaccine. 2011;29:2461–73. doi:https://doi.org/10.1016/j.vaccine.2011.01.011.
   PubMed Web of Science ®Google Scholar
• Sobolev O, Binda E, O’Farrell S, Lorenc A, Pradines J, Huang Y, Duffner J, Schulz R, Cason J, Zambon M, et al. Adjuvanted influenza-H1N1 vaccination reveals lymphoid signatures of age-dependent early responses and of clinical adverse events. Nat Immunol. 2016;17(2):204–13. doi:https://doi.org/10.1038/ni.3328.
   PubMed Web of Science ®Google Scholar
• Howard LM, Hoek KL, Goll JB, Samir P, Galassie A, Allos TM, Niu X, Gordy LE, Creech CB, Prasad N, et al. Cell-based systems biology analysis of human AS03-adjuvanted H5N1 avian influenza vaccine responses: a phase i randomized controlled trial. PLoS One. 2017;12(1):e0167488. doi:https://doi.org/10.1371/journal.pone.0167488.
   PubMed Web of Science ®Google Scholar
• Pallikkuth S, Parmigiani A, Silva SY, George VK, Fischl M, Pahwa R, et al. Impaired peripheral blood T-follicular helper cell function in HIV-infected nonresponders to the 2009 H1N1/09 vaccine. Blood. 2012;120:985–93. doi:https://doi.org/10.1182/blood-2011-12-396648.
   PubMed Web of Science ®Google Scholar
• Fernandez-Ruiz M, Humar A, Baluch A, Keshwani S, Husain S, Kumar D. Baseline serum interleukin-6 to interleukin-2 ratio is associated with the response to seasonal trivalent influenza vaccine in solid organ transplant recipients. Vaccine. 2015;33(51):7176–82. doi:https://doi.org/10.1016/j.vaccine.2015.10.134.
   PubMed Web of Science ®Google Scholar
• Spensieri F, Borgogni E, Zedda L, Bardelli M, Buricchi F, Volpini G, Fragapane E, Tavarini S, Finco O, Rappuoli R, et al. Human circulating influenza-CD4+ ICOS1+IL-21+ T cells expand after vaccination, exert helper function, and predict antibody responses. Proc Natl Acad Sci U S A. 2013;110(35):14330–35. doi:https://doi.org/10.1073/pnas.1311998110.
   PubMed Web of Science ®Google Scholar
• Pallikkuth S, Pilakka Kanthikeel S, Silva SY, Fischl M, Pahwa R, Pahwa S. Upregulation of IL-21 receptor on B cells and IL-21 secretion distinguishes novel 2009 H1N1 vaccine responders from nonresponders among HIV-infected persons on combination antiretroviral therapy. J Immunol. 2011;186(11):6173–81. doi:https://doi.org/10.4049/jimmunol.1100264.
   PubMed Web of Science ®Google Scholar
• Galli G, Medini D, Borgogni E, Zedda L, Bardelli M, Malzone C, Nuti S, Tavarini S, Sammicheli C, Hilbert AK, et al. Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels. Proc Natl Acad Sci U S A. 2009;106(10):3877–82. doi:https://doi.org/10.1073/pnas.0813390106.
   PubMed Web of Science ®Google Scholar